Chesapeake Biological Laboratories Announces FDA Approval for Commercial Manufacturing

Strategic Insights -

Chesapeake Biological Laboratories, Inc., a Baltimore-based pharmaceutical and medical device developer, has announced that one of its clients has received FDA approval for commercial manufacturing. Additionally, a second client has received a FDA approvable letter, signifying the final step before FDA clearance for marketing in the United States. The third client's approval is based on FDA verification of additional work being performed at CBL. These approvals mark a significant milestone for the company, as they represent the first new products to receive approval status for commercial manufacturing in the company's new Camden facility.

Key Takeaways:

  • Chesapeake Biological Laboratories has announced FDA approval for commercial manufacturing for one client, with a second client receiving a FDA approvable letter and a third client receiving FDA verification of additional work.
  • The approvals mark a significant milestone for the company, representing the first new products to receive approval status for commercial manufacturing in the company's new Camden facility.
  • The company's President and CEO, Thomas P. Rice, has stated that these products may provide annual commercial manufacturing revenue of as much as $4 to $5 million.
  • Chesapeake Biological Laboratories specializes in formulating, filling, and packaging sterile injectable biopharmaceutical and pharmaceutical products.
  • The company has contributed to the development and production of more than 100 therapeutic products and serves a broad range of life sciences customers.

Statistics:

  • 1 client has received FDA approval for commercial manufacturing
  • 1 client has received a FDA approvable letter
  • 1 client's approval is based on FDA verification of additional work
  • $4 to $5 million in potential annual commercial manufacturing revenue
  • Over 100 therapeutic products developed and produced
  • 1 new facility (Camden) for commercial manufacturing

Sources:

  • PRNewswire (Baltimore, June 1)
  • Chesapeake Biological Laboratories, Inc. (Last accessed on the provided PRNewswire date)
  • Section 21E of the Securities Exchange Act of 1934 (Last accessed on the provided PRNewswire date)